Bank of New York Mellon
STRO icon

Bank of New York Mellon’s Sutro Biopharma STRO Stock Holding History

Bank of New York Mellon’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
+41,369
New +$1.29M ﹤0.01% 3176
2025
Q2 		– Sell
-20,922
Closed -$136K – 4262
2025
Q1 		$136K Sell
20,922
-841
-4% -$13.2K ﹤0.01% 3963
2024
Q4 		$400K Buy
21,763
+258
+1% +$7.88K ﹤0.01% 3632
2024
Q3 		$744K Sell
21,505
-5,767
-21% -$226K ﹤0.01% 3298
2024
Q2 		$799K Buy
27,272
+8,803
+48% +$348K ﹤0.01% 3321
2024
Q1 		$1.04M Sell
18,469
-7,793
-30% -$344K ﹤0.01% 3129
2023
Q4 		$1.13M Buy
26,262
+117
+0.4% +$3.71K ﹤0.01% 3128
2023
Q3 		$907K Buy
26,145
+863
+3% +$37.6K ﹤0.01% 3211
2023
Q2 		$1.18M Buy
25,282
+1,258
+5% +$62.6K ﹤0.01% 3109
2023
Q1 		$1.11M Buy
24,024
+153
+0.6% +$9.71K ﹤0.01% 3092
2022
Q4 		$1.93M Buy
23,871
+8,284
+53% +$576K ﹤0.01% 2872
2022
Q3 		$865K Buy
15,587
+1,889
+14% +$112K ﹤0.01% 3278
2022
Q2 		$714K Sell
13,698
-1,364
-9% -$76.2K ﹤0.01% 3373
2022
Q1 		$1.24M Buy
15,062
+100
+0.7% +$9.52K ﹤0.01% 3179
2021
Q4 		$2.23M Sell
14,962
-1,726
-10% -$309K ﹤0.01% 2931
2021
Q3 		$3.15M Buy
16,688
+1,328
+9% +$253K ﹤0.01% 2740
2021
Q2 		$2.86M Buy
15,360
+5,220
+51% +$1.02M ﹤0.01% 2780
2021
Q1 		$2.31M Buy
10,140
+58
+0.6% +$13.8K ﹤0.01% 2844
2020
Q4 		$2.19M Buy
10,082
+3,946
+64% +$653K ﹤0.01% 2795
2020
Q3 		$617K Buy
6,136
+1,145
+23% +$108K ﹤0.01% 3384
2020
Q2 		$387K Buy
4,991
+2,106
+73% +$202K ﹤0.01% 3595
2020
Q1 		$295K Buy
2,885
+1
+0% +$105 ﹤0.01% 3608
2019
Q4 		$317K Hold
2,884
– – ﹤0.01% 3785
2019
Q3 		$262K Sell
2,884
-163
-5% -$16.5K ﹤0.01% 3823
2019
Q2 		$347K Buy
3,047
+1,559
+105% +$172K ﹤0.01% 3756
2019
Q1 		$169K Buy
+1,488
New +$155K ﹤0.01% 3919

Other funds holding STRO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's STRO Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Sutro Biopharma (STRO) in Q2 2026: 41,369 shares worth $1.37M. The stake represents ﹤0.01% of the portfolio and ranks #3176 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in STRO as recently as Q1 2025.

Bank of New York Mellon first reported a position in STRO in Q1 2019 and has held it in 26 quarters since. The position peaked at $3.15M in Q3 2021. 29 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Bank of New York Mellon held 41,369 shares of Sutro Biopharma worth $1.37M as of Q2 2026.
  • Sutro Biopharma was a new Bank of New York Mellon position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3176 holding.
  • Bank of New York Mellon first reported a position in Sutro Biopharma in Q1 2019 and has held it in 26 quarters since.
  • Bank of New York Mellon's Sutro Biopharma position peaked at $3.15M in Q3 2021.
  • 29 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.